PURPOSE: s: Although the standard management of @entity5 is concurrent @entity902 -based chemotherapy with thoracic radiotherapy (TRT), the optimal timing of the TRT remains controversial. We investigated the feasibility of concurrent chemoradiation for the @entity1 with @entity5 after 2 cycles of combination chemotherapy with @entity2879 / @entity900 (EP). MATERIALS AND METHODS: EP consisted of @entity2879 100 mg/m2 on day 1 to 3 and @entity900 70 mg/m2 on day 1. Six cycles were given to the responders every 4 weeks. Total 55 Gy (1.8 Gy once-daily or 1.2 Gy twice-daily, 5 days per week) of TRT were given to the @entity1 who showed at least a partial response after 2 cycles of EP. The other @entity1 were treated by the physician's decision. The @entity1 with complete remission were recommended to receive prophylactic cranial irradiation. RESULTS: Fifty @entity1 were enrolled. Thirty-five (70%) of them showed responses (2 complete remissions and 33 partial remissions) after 2 cycles of EP. Thirty-three of the responders were given TRT starting with the 3rd cycle of EP. The nonresponders were treated with salvage chemotherapy and TRT. After completion of treatment for 50 @entity1 , the overall response rate was 86% (29 complete remissions, 14 partial remissions). One @entity1 (2%) showed stable disease, and 6 (12%) showed a progressive disease. The median progression free survival was 326 days and the median survival time was 410 days. One-, 2-, 3-, 4- and 5-year survival rates were 62%, 24%, 14%, 9% and 6%, respectively. As hematologic @entity137 during chemoradiation, 35.1% with grade III/IV @entity1398 and 18.9% with grade III/IV @entity882 were noted. @entity1207 and @entity1208 were noted in 5/1 and 13/1 @entity1 (15.2%/ 3.0% and 39.4%/3.0%), respectively. One @entity1 died of @entity295 during chemoradiation. CONCLUSION: The concurrent EP and TRT after 2 cycles of EP was feasible in @entity5 . Further study is required for the indentification of optimum timing of TRT during combination chemotherapy.

Concurrent @entity2879 / XXXX Combination Chemotherapy (EP) and Thoracic Radiotherapy after Two Cycles of EP for @entity5 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['limited stage small cell lung cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['Cisplatin'] @entity2879 :: ('MESH:D005047', 'Chemical') :: ['Etoposide'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1207 :: ('MESH:D017564', 'Disease') :: ['Grade II/III radiation pneumonitis'] @entity1208 :: ('MESH:D004935', 'Disease') :: ['radiation esophagitis'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity900 :: (MESH:D002945,Chemical) :: ['Cisplatin']
